Business Context and Reporting Period
This Form 8-K is a current report filed by Fluidigm Corporation (not Standard BioTools Inc.) on January 22, 2013. The filing discloses specific compensatory arrangements for the company's President and Chief Executive Officer, Gajus V. Worthington, approved by the Board of Directors.
Key Financial Metrics
The filing does not provide general financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The only financial figures disclosed relate to executive compensation:
- CEO Base Salary Adjustment: Increased from $350,000 to $425,000 annually, effective January 1, 2013.
- Fiscal 2012 Bonus: A one-time bonus payment of $175,000 was approved for Mr. Worthington.
- Fiscal 2013 Bonus Target: Set at 50% of the annual base salary.
Material Changes
The material change reported is the adjustment to the CEO's compensation package. There are no reported changes to the company's financial position, operations, or capital structure in this document.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on business outlook, or discussion of risks and contingencies. The compensation determinations were made by the Board of Directors, excluding Mr. Worthington, based on the recommendation of the Compensation Committee.
Key Facts for Investor Verification
- Verify the correct registrant name is Fluidigm Corporation, as the metadata reference to "Standard BioTools Inc." appears to be an error in the request context.
- Confirm the effective date of the salary increase (January 1, 2013) versus the filing date (January 22, 2013).
- Note that the $175,000 bonus relates to fiscal 2012 performance, while the new salary and bonus target apply to fiscal 2013.
- Understand that this filing does not contain financial statements or operational metrics.